Sonrai Partners with Candel Therapeutics to Advance The Development of Viral Immunotherapies for Cancer

Sonrai Partners with Candel Therapeutics to Advance The Development of Viral Immunotherapies for Cancer

Sharing Knowledge

Sonrai Partners with Candel Therapeutics to Advance The Development of Viral Immunotherapies for Cancer

The partnership harnesses Sonrai's AI data management and analysis platform to enable Candel to identify biomarkers predictive of response and determine the mechanism of action of its investigational therapeutics.

PRESS RELEASE
Belfast, Northern Ireland 05/03/2024

Sonrai Analytics (Sonrai), an AI precision medicine company enabling advanced analytics to advance the development of therapeutics, and Candel Therapeutics (Candel), a clinical-stage biopharmaceutical company focused on developing multi-modal biological immunotherapies, today announced a strategic partnership to accelerate the development of novel cancer therapeutics. The partnership brings Sonrai’s innovative cloud-based AI technology to Candel’s pipeline, allowing Candel to integrate and analyze clinical trial data to support the identification of predictive biomarkers of response to treatment.

Candel will utilize Sonrai’s AI technology platform, Sonrai Discovery, to integrate and analyze its diverse data types, including multi-omics, imaging, and clinical data. Sonrai Discovery will enable Candel to create scalable workflows and visualizations, simplifying and accelerating biomarker discovery, management and analysis through efficient biomarker shortlisting and reporting. The platform will facilitate the interrogation and sharing of multi-omics data to allow researchers at Candel to advance the development of cancer therapeutics without data silos and duplication of effort. 

Multi-omics data generated in ongoing clinical trials in lung cancer and pancreatic cancer will be interrogated using Sonrai’s AI platform. Potential interactions between baseline patient characteristics, post-treatment biological and measures of clinical outcome will be integrated, providing a holistic evaluation of the clinical and biological response to Candel’s investigational medicines. 

“We are committed to bringing innovation through AI to our partners developing groundbreaking therapeutics to save patients’ lives. The ability to integrate multi-omics data with imaging data is a key innovation in the Sonrai platform, which allows drug developers to maximize outputs from their data and gain new insights ”, said Prof. Darragh McArt, CEO and Founder, Sonrai Analytics. “We are proud to be working with Candel Therapeutics to help bring highly innovative off-the-shelf immunotherapies to patients.”

“At Candel we have previously implemented AI in our enLIGHTENTM Discovery Platform. By partnering with Sonrai, we are able to expand the scope of computational biology and AI to our clinical data”, said Francesca Barone, M.D., Ph.D., Chief Scientific Officer at Candel Therapeutics. “Being able to integrate multi-omics data with imaging and clinical data allows us to accelerate our goal to treat cancer patients with precision.”

 

About Sonrai Analytics

Sonrai Analytics, founded in 2018 by Prof. Darragh McArt and Dr. Deva Senevirathne, is an AI precision medicine technology company. Sonrai’s flagship product, Sonrai Discovery, expedites identifying and developing drug or therapeutic targets, improving patient outcomes through AI. The company partners with biotechnology and pharmaceutical companies to manage and analyze their precision medicine data. By leveraging Sonrai Discovery, these companies can confidently select compounds with the highest potential for success in clinical trials, accelerating drug development and mitigating the risk of failures during human trials.

With a proven track record, Sonrai has successfully deployed its technology with prominent healthcare businesses across the EU and the US. Additionally, Sonrai continues to forge strategic partnerships (including NHS) that will further enhance commercial operations and scale impact.

For additional information about Sonrai, please visit: sonraianalytics.com. To speak with one of our experts, book a chat with us here.

 

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

 

For Sonrai media enquiries contact:

Hanna Bielecka

Content Marketing Manager

Sonrai Analytics

h.bielecka@sonraianalytics.com

 

For Candel media enquiries contact:

Aljanae Reynolds

Director

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com 

Discover how Sonrai Cloud transformed our clients data analysis and reporting for their immunotherapy clinical trial. Click to explore the case study and learn more.

Subscribe to stay up to date with the latest Sonrai content.
Related Posts